INTRODUCTION

Atezolizumab (brand name Tecentriq) is a humanized monoclonal antibody of IgG1 isotype targeting the programmed cell death-ligand 1 (PD-L1) to prevent the interaction of PD-L1 and PD-1. Atezolizumab is used in the treatment of advanced or metastatic urothelial carcinoma, triple-negative breast cancer (TNBC), hepatocellular carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and alveolar soft part sarcoma.

This plasmid is designed for expressing Atezolizumab in mammalian cells such as HEK293, or Chinese hamster ovary (CHO) cell line. We provide multiple options for Atezolizumab expression, either single-vector-based expression or two-vector-based expression.

PRODUCT INFORMATION

Item No.: PPBD-28
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Atezolizumab
Brand Names: Tecentriq
Classification: Monoclonal antibody (mAb)
Target: Programmed cell death-ligand 1 (PD-L1), CD274
Action Type: Inhibitor
Amino Acid Sequence: Identical to DB11595

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Markham A. Atezolizumab: First Global Approval. Drugs. 2016 Aug;76(12):1227-32.

[2] Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20.

Contact Us